Audit Report Correction: Qualified Opinion, Adverse Internal Control, Fraud Disclosure
-
Audit opinion downgraded from unqualified to qualified due to scope limitation
-
Internal accounting control system opinion changed to adverse
-
Embezzlement/breach of trust disclosed in audit report
-
Current financials: Total assets 114,973M KRW, liabilities 75,171M KRW, equity 39,802M KRW (capital erosion ratio -52.5%)
-
Revenue 88,594M KRW, operating profit 596M KRW, net loss 2,074M KRW (continued net loss vs prior year)
-
Capital stock 26,101M KRW vs equity 39,802M KRW (no capital impairment but debt ratio 188.8%)
-
Audit report receipt date: 2026-04-30 (overdue)
KOSPI Filing Information
-
Filing: [Correction of Description] Audit Report Submission
-
Company: Dongsung Pharmaceutical (002210)
-
Submission: Dongsung Pharmaceutical Co., Ltd.
-
Receipt: 04-30-2026
-
Under KRX KOSPI Market Division